Clinical Study
Lower Viral Response to Pegylated Interferon Alpha 2a Treatment of Chronic Hepatitis B in Roma People in Eastern Slovakia
Table 1
Baseline demographic and virological parameters of the study cohort.
| | Roma | Non-Roma | |
| Count | 43 | 46 | | Age (years ± SD) | 33 ± 8.3 | 35 ± 7.5 | 0.081 | Women | 11 (25.6%) | 13 (28.3%) | 0.680 | HBeAg posit | 9 (20.9%) | 4 (8.7%) | 0.093 | HBV DNA IU/mL (median(IQR)) | 40900 (28900–588000) | 27550 (3300–223367) | 0.025 | HBV DNA < 2000 IU/mL | 3 (9.3%) | 7 (15.2%) | 0.219 | ALT > 2 ULN | 22 (51.2%) | 21 (45.7%) | 0.603 | Staging (Metavir) | 1.64 ± 1.07 | 1.34 ± 1.04 | 0.382 | Grading (Metavir) | 1.91 ± 0.87 | 2.0 ± 0.76 | 0.795 | Cirrhosis | 3 (7.0%) | 5 (10.9%) | 0.521 |
|
|
ALT: alanine aminotransferase.
|